Stephen Eckert

4.3k total citations · 2 hit papers
29 papers, 2.8k citations indexed

About

Stephen Eckert is a scholar working on Oncology, Physiology and Hematology. According to data from OpenAlex, Stephen Eckert has authored 29 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Physiology and 7 papers in Hematology. Recurrent topics in Stephen Eckert's work include Lysosomal Storage Disorders Research (8 papers), Acute Myeloid Leukemia Research (7 papers) and Estrogen and related hormone effects (6 papers). Stephen Eckert is often cited by papers focused on Lysosomal Storage Disorders Research (8 papers), Acute Myeloid Leukemia Research (7 papers) and Estrogen and related hormone effects (6 papers). Stephen Eckert collaborates with scholars based in United States, United Kingdom and France. Stephen Eckert's co-authors include Marc E. Lippman, Jane A. Cauley, Larry Norton, Steven R. Cummings, Thomas Nickélsen, J. E. Glusman, Monica Morrow, N. H. Bjarnason, T.J. Powles and V. Craig Jordan and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephen Eckert

28 papers receiving 2.7k citations

Hit Papers

The Effect of Raloxifene on Risk of Breast Cancer in Post... 1999 2026 2008 2017 1999 2001 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women
    1999 1.4k citations Steven R. Cummings, Stephen Eckert et al. JAMA profile →
  2. Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
    2001 505 citations Jane A. Cauley, Larry Norton et al. Breast Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen Eckert United States 14 1.6k 1.1k 629 552 551 29 2.8k
A. Costa Italy 27 2.0k 1.2× 1.8k 1.6× 1.2k 1.8× 273 0.5× 1.1k 2.0× 73 4.2k
N. H. Bjarnason Denmark 18 1.3k 0.9× 1.2k 1.1× 793 1.3× 1.4k 2.5× 343 0.6× 31 3.1k
Trevor J. Powles United Kingdom 32 2.6k 1.6× 2.7k 2.4× 1.1k 1.7× 690 1.3× 1.6k 2.8× 65 5.2k
M Baum United Kingdom 11 2.4k 1.5× 2.0k 1.8× 455 0.7× 230 0.4× 1.6k 2.9× 34 3.6k
T.J. Powles United Kingdom 34 3.4k 2.2× 3.8k 3.3× 1.2k 1.8× 624 1.1× 2.4k 4.3× 82 6.9k
Mary Jane Geiger United States 20 640 0.4× 568 0.5× 452 0.7× 685 1.2× 237 0.4× 31 2.5k
Pamela W. Anderson United States 26 871 0.6× 350 0.3× 524 0.8× 263 0.5× 130 0.2× 41 2.6k
Samuel Wieand United States 8 2.6k 1.7× 2.2k 2.0× 960 1.5× 110 0.2× 1.6k 2.9× 10 4.9k
Harriet Johansson Italy 29 845 0.5× 1.0k 0.9× 846 1.3× 49 0.1× 710 1.3× 83 2.5k
J. E. Glusman United States 10 1.1k 0.7× 794 0.7× 358 0.6× 318 0.6× 369 0.7× 17 2.1k

Countries citing papers authored by Stephen Eckert

Since Specialization
Citations

This map shows the geographic impact of Stephen Eckert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Eckert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Eckert more than expected).

Fields of papers citing papers by Stephen Eckert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Eckert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Eckert. The network helps show where Stephen Eckert may publish in the future.

Co-authorship network of co-authors of Stephen Eckert

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Eckert. A scholar is included among the top collaborators of Stephen Eckert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Eckert. Stephen Eckert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rasco, Drew, Sabine Eckhardt, Diwakar Davar, et al.. (2018). Abstract CT030: Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors. Cancer Research. 78(13_Supplement). CT030–CT030. 4 indexed citations
2.
Jones, Simon, Sandra Rojas-Caro, Anthony Quinn, et al.. (2017). Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet Journal of Rare Diseases. 12(1). 25–25. 56 indexed citations
3.
Jones, Simon, Dominique Plantaz, Roshni Vara, et al.. (2015). Effect of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency. Molecular Genetics and Metabolism. 114(2). S59–S59. 6 indexed citations
4.
Whitley, Chester B., Vassili Valayannopoulos, Reena Sharma, et al.. (2014). Long-term clinical effect and safety of sebelipase alfa in adults with lysosomal acid lipase deficiency. Molecular Genetics and Metabolism. 111(2). S113–S114. 2 indexed citations
5.
Balwani, Manisha, Catherine Breen, Gregory M. Enns, et al.. (2013). Clinical Effect And Safety Profile of Recombinant Human Lysosomal Acid Lipase in Patients With Cholesteryl Ester Storage Disease. Hepatology. 58(3). 950–957. 77 indexed citations
6.
Faderl, Stefan, Meir Wetzler, David A. Rizzieri, et al.. (2011). Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.. Journal of Clinical Oncology. 29(15_suppl). 6503–6503. 6 indexed citations
7.
8.
Kantarjian, Hagop M., Harry P. Erba, David F. Claxton, et al.. (2009). Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors. Journal of Clinical Oncology. 28(4). 549–555. 148 indexed citations
9.
10.
Erba, Harry P., Hagop M. Kantarjian, David F. Claxton, et al.. (2008). Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 7025–7025. 8 indexed citations
11.
Brown, Mark J., et al.. (2004). Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population. Diabetes Care. 27(5). 1153–1159. 60 indexed citations
12.
Freedman, Matthew T., Jeffrey S. Martin, John O’Gorman, et al.. (2001). Digitized Mammography: a Clinical Trial of Postmenopausal Women Randomly Assigned to Receive Raloxifene, Estrogen, or Placebo. JNCI Journal of the National Cancer Institute. 93(1). 51–56. 104 indexed citations
13.
Lippman, Marc E., Kathryn A. Krueger, Stephen Eckert, et al.. (2001). Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants. Obstetrical & Gynecological Survey. 56(11). 698–700. 5 indexed citations
14.
Cauley, Jane A., Larry Norton, Marc E. Lippman, et al.. (2001). Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. Breast Cancer Research and Treatment. 65(2). 125–134. 505 indexed citations breakdown →
15.
Cummings, Steven R., Stephen Eckert, Kathryn A. Krueger, et al.. (2000). The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial. Obstetrical & Gynecological Survey. 55(2). 100–100. 73 indexed citations
16.
Ettinger, Bruce, Dennis M. Black, Bruce Mitlak, et al.. (2000). Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial. Obstetrical & Gynecological Survey. 55(1). 39–39. 116 indexed citations
17.
Cummings, Steven R., Lisa Palermo, Warren S. Browner, et al.. (2000). Monitoring Osteoporosis Therapy With Bone Densitometry: Misleading Changes and Regression to the Mean. Obstetrical & Gynecological Survey. 55(8). 498–499. 8 indexed citations
18.
Cummings, Steven R., Stephen Eckert, D Grady, et al.. (1999). The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women. JAMA. 281(23). 2189–2189. 1398 indexed citations breakdown →
19.
Cohen, Fredric J., Stephen Eckert, & Bruce Mitlak. (1998). Geographic Differences in Bone Turnover: Data from a Multinational Study in Healthy Postmenopausal Women. Calcified Tissue International. 63(4). 277–282. 24 indexed citations
20.
Glusman, J. E., Yifei Lü, William J. Huster, et al.. (1997). P-26.. Menopause The Journal of The North American Menopause Society. 4(4). 260–260. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Costa Breakdown of academic impact, for papers by N. H. Bjarnason Breakdown of academic impact, for papers by Trevor J. Powles Breakdown of academic impact, for papers by M Baum Breakdown of academic impact, for papers by T.J. Powles Breakdown of academic impact, for papers by Mary Jane Geiger Breakdown of academic impact, for papers by Pamela W. Anderson Breakdown of academic impact, for papers by Samuel Wieand Breakdown of academic impact, for papers by Harriet Johansson Breakdown of academic impact, for papers by J. E. Glusman
Rankless by CCL
2026